Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
oleh: Giovanna Lalli, Jonathan M Schott, John Hardy, Bart De Strooper
| Format: | Article |
|---|---|
| Diterbitkan: | Springer Nature 2021-08-01 |
Deskripsi
On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.